nodes	percent_of_prediction	percent_of_DWPC	metapath
Ponatinib—ABL1—esophageal cancer	0.293	0.491	CbGaD
Ponatinib—KDR—esophageal cancer	0.25	0.418	CbGaD
Ponatinib—ABCB1—esophageal cancer	0.0543	0.0909	CbGaD
Ponatinib—ABCG2—Carboplatin—esophageal cancer	0.0278	0.343	CbGbCtD
Ponatinib—ABCG2—Cisplatin—esophageal cancer	0.0238	0.293	CbGbCtD
Ponatinib—ABCG2—Methotrexate—esophageal cancer	0.0154	0.19	CbGbCtD
Ponatinib—ABCB1—Cisplatin—esophageal cancer	0.00857	0.106	CbGbCtD
Ponatinib—ABCB1—Methotrexate—esophageal cancer	0.00557	0.0686	CbGbCtD
Ponatinib—FGFR2—exocrine gland—esophageal cancer	0.00262	0.0397	CbGeAlD
Ponatinib—FGFR4—digestive system—esophageal cancer	0.00194	0.0294	CbGeAlD
Ponatinib—KIT—exocrine gland—esophageal cancer	0.00182	0.0276	CbGeAlD
Ponatinib—RET—neck—esophageal cancer	0.00176	0.0267	CbGeAlD
Ponatinib—FGFR3—epithelium—esophageal cancer	0.00174	0.0264	CbGeAlD
Ponatinib—FGFR3—bronchus—esophageal cancer	0.00171	0.026	CbGeAlD
Ponatinib—FGFR2—neck—esophageal cancer	0.00167	0.0254	CbGeAlD
Ponatinib—FGFR4—lung—esophageal cancer	0.00162	0.0246	CbGeAlD
Ponatinib—BCR—bronchus—esophageal cancer	0.00148	0.0225	CbGeAlD
Ponatinib—BCR—trachea—esophageal cancer	0.00133	0.0202	CbGeAlD
Ponatinib—FGFR1—bronchus—esophageal cancer	0.00132	0.02	CbGeAlD
Ponatinib—KDR—neck—esophageal cancer	0.00131	0.0199	CbGeAlD
Ponatinib—RET—epithelium—esophageal cancer	0.0012	0.0182	CbGeAlD
Ponatinib—LCK—bronchus—esophageal cancer	0.00118	0.0179	CbGeAlD
Ponatinib—KIT—neck—esophageal cancer	0.00116	0.0176	CbGeAlD
Ponatinib—FGFR2—epithelium—esophageal cancer	0.00114	0.0173	CbGeAlD
Ponatinib—FGFR4—lymph node—esophageal cancer	0.00111	0.0168	CbGeAlD
Ponatinib—FGFR3—lung—esophageal cancer	0.00111	0.0168	CbGeAlD
Ponatinib—FGFR2—smooth muscle tissue—esophageal cancer	0.0011	0.0166	CbGeAlD
Ponatinib—TEK—epithelium—esophageal cancer	0.00109	0.0166	CbGeAlD
Ponatinib—TEK—bronchus—esophageal cancer	0.00108	0.0163	CbGeAlD
Ponatinib—LCK—trachea—esophageal cancer	0.00106	0.0161	CbGeAlD
Ponatinib—Nilotinib—ABL1—esophageal cancer	0.00105	0.184	CrCbGaD
Ponatinib—TEK—smooth muscle tissue—esophageal cancer	0.00105	0.016	CbGeAlD
Ponatinib—SRC—epithelium—esophageal cancer	0.00097	0.0147	CbGeAlD
Ponatinib—Nilotinib—CA1—esophageal cancer	0.000962	0.168	CrCbGaD
Ponatinib—BCR—lung—esophageal cancer	0.000956	0.0145	CbGeAlD
Ponatinib—PDGFRA—smooth muscle tissue—esophageal cancer	0.000953	0.0145	CbGeAlD
Ponatinib—FLT3—lung—esophageal cancer	0.00095	0.0144	CbGeAlD
Ponatinib—SRC—smooth muscle tissue—esophageal cancer	0.000935	0.0142	CbGeAlD
Ponatinib—RET—digestive system—esophageal cancer	0.000912	0.0138	CbGeAlD
Ponatinib—KDR—epithelium—esophageal cancer	0.000892	0.0135	CbGeAlD
Ponatinib—ABCB11—digestive system—esophageal cancer	0.00089	0.0135	CbGeAlD
Ponatinib—KDR—bronchus—esophageal cancer	0.000879	0.0133	CbGeAlD
Ponatinib—Imatinib—ABL1—esophageal cancer	0.000877	0.153	CrCbGaD
Ponatinib—PDGFRA—trachea—esophageal cancer	0.000875	0.0133	CbGeAlD
Ponatinib—FGFR2—digestive system—esophageal cancer	0.000866	0.0131	CbGeAlD
Ponatinib—KDR—smooth muscle tissue—esophageal cancer	0.00086	0.013	CbGeAlD
Ponatinib—FGFR1—lung—esophageal cancer	0.000851	0.0129	CbGeAlD
Ponatinib—Imatinib—CA1—esophageal cancer	0.000803	0.14	CrCbGaD
Ponatinib—KIT—epithelium—esophageal cancer	0.000791	0.012	CbGeAlD
Ponatinib—KDR—trachea—esophageal cancer	0.000789	0.012	CbGeAlD
Ponatinib—KIT—bronchus—esophageal cancer	0.000779	0.0118	CbGeAlD
Ponatinib—KIT—smooth muscle tissue—esophageal cancer	0.000762	0.0116	CbGeAlD
Ponatinib—LCK—lung—esophageal cancer	0.000761	0.0115	CbGeAlD
Ponatinib—PDGFRA—digestive system—esophageal cancer	0.000752	0.0114	CbGeAlD
Ponatinib—SRC—digestive system—esophageal cancer	0.000738	0.0112	CbGeAlD
Ponatinib—Nilotinib—CA2—esophageal cancer	0.000729	0.127	CrCbGaD
Ponatinib—FGFR2—lung—esophageal cancer	0.000723	0.011	CbGeAlD
Ponatinib—KIT—trachea—esophageal cancer	0.000699	0.0106	CbGeAlD
Ponatinib—TEK—lung—esophageal cancer	0.000694	0.0105	CbGeAlD
Ponatinib—KDR—digestive system—esophageal cancer	0.000679	0.0103	CbGeAlD
Ponatinib—ABL1—bronchus—esophageal cancer	0.000678	0.0103	CbGeAlD
Ponatinib—ABL1—smooth muscle tissue—esophageal cancer	0.000663	0.0101	CbGeAlD
Ponatinib—BCR—lymph node—esophageal cancer	0.000654	0.00992	CbGeAlD
Ponatinib—FLT3—lymph node—esophageal cancer	0.000649	0.00985	CbGeAlD
Ponatinib—PDGFRA—lung—esophageal cancer	0.000628	0.00953	CbGeAlD
Ponatinib—SRC—lung—esophageal cancer	0.000616	0.00935	CbGeAlD
Ponatinib—ABL1—trachea—esophageal cancer	0.000609	0.00923	CbGeAlD
Ponatinib—Imatinib—CA2—esophageal cancer	0.000608	0.106	CrCbGaD
Ponatinib—KIT—digestive system—esophageal cancer	0.000602	0.00912	CbGeAlD
Ponatinib—FGFR1—lymph node—esophageal cancer	0.000582	0.00883	CbGeAlD
Ponatinib—KDR—lung—esophageal cancer	0.000567	0.0086	CbGeAlD
Ponatinib—ABL1—digestive system—esophageal cancer	0.000524	0.00794	CbGeAlD
Ponatinib—RET—lymph node—esophageal cancer	0.000521	0.0079	CbGeAlD
Ponatinib—LCK—lymph node—esophageal cancer	0.000521	0.0079	CbGeAlD
Ponatinib—Mucosal inflammation—Methotrexate—esophageal cancer	0.000513	0.00529	CcSEcCtD
Ponatinib—KIT—lung—esophageal cancer	0.000502	0.00762	CbGeAlD
Ponatinib—Pleural effusion—Capecitabine—esophageal cancer	0.000498	0.00514	CcSEcCtD
Ponatinib—Body temperature increased—Carboplatin—esophageal cancer	0.000497	0.00513	CcSEcCtD
Ponatinib—Skin exfoliation—Cisplatin—esophageal cancer	0.000494	0.00509	CcSEcCtD
Ponatinib—Hepatotoxicity—Capecitabine—esophageal cancer	0.000494	0.00509	CcSEcCtD
Ponatinib—Fluid retention—Cisplatin—esophageal cancer	0.000491	0.00506	CcSEcCtD
Ponatinib—Hyperaesthesia—Capecitabine—esophageal cancer	0.000486	0.00501	CcSEcCtD
Ponatinib—Neuropathy—Cisplatin—esophageal cancer	0.000486	0.00501	CcSEcCtD
Ponatinib—TEK—lymph node—esophageal cancer	0.000474	0.00719	CbGeAlD
Ponatinib—Myocardial ischaemia—Capecitabine—esophageal cancer	0.000474	0.00489	CcSEcCtD
Ponatinib—Febrile neutropenia—Methotrexate—esophageal cancer	0.000472	0.00487	CcSEcCtD
Ponatinib—Deep vein thrombosis—Methotrexate—esophageal cancer	0.000467	0.00481	CcSEcCtD
Ponatinib—Petechiae—Capecitabine—esophageal cancer	0.000463	0.00478	CcSEcCtD
Ponatinib—Dysphonia—Capecitabine—esophageal cancer	0.000463	0.00478	CcSEcCtD
Ponatinib—Folliculitis—Methotrexate—esophageal cancer	0.000452	0.00466	CcSEcCtD
Ponatinib—ABL1—lung—esophageal cancer	0.000437	0.00663	CbGeAlD
Ponatinib—PDGFRA—lymph node—esophageal cancer	0.00043	0.00652	CbGeAlD
Ponatinib—Gastrooesophageal reflux disease—Capecitabine—esophageal cancer	0.000422	0.00435	CcSEcCtD
Ponatinib—SRC—lymph node—esophageal cancer	0.000421	0.00639	CbGeAlD
Ponatinib—Cellulitis—Capecitabine—esophageal cancer	0.000419	0.00432	CcSEcCtD
Ponatinib—Hypocalcaemia—Capecitabine—esophageal cancer	0.000416	0.0043	CcSEcCtD
Ponatinib—Cardiac failure congestive—Cisplatin—esophageal cancer	0.000414	0.00427	CcSEcCtD
Ponatinib—Blood bilirubin increased—Capecitabine—esophageal cancer	0.000403	0.00416	CcSEcCtD
Ponatinib—Bone pain—Capecitabine—esophageal cancer	0.000398	0.00411	CcSEcCtD
Ponatinib—KDR—lymph node—esophageal cancer	0.000388	0.00588	CbGeAlD
Ponatinib—Neck pain—Capecitabine—esophageal cancer	0.000386	0.00398	CcSEcCtD
Ponatinib—Cerebrovascular accident—Cisplatin—esophageal cancer	0.000383	0.00395	CcSEcCtD
Ponatinib—Pulmonary embolism—Capecitabine—esophageal cancer	0.000381	0.00393	CcSEcCtD
Ponatinib—Phosphatase alkaline increased—Capecitabine—esophageal cancer	0.000381	0.00393	CcSEcCtD
Ponatinib—Hyponatraemia—Cisplatin—esophageal cancer	0.000377	0.00389	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Cisplatin—esophageal cancer	0.000375	0.00387	CcSEcCtD
Ponatinib—Pleural effusion—Methotrexate—esophageal cancer	0.000371	0.00382	CcSEcCtD
Ponatinib—Influenza like illness—Capecitabine—esophageal cancer	0.00037	0.00382	CcSEcCtD
Ponatinib—Hepatotoxicity—Methotrexate—esophageal cancer	0.000368	0.00379	CcSEcCtD
Ponatinib—Skin exfoliation—Capecitabine—esophageal cancer	0.000364	0.00375	CcSEcCtD
Ponatinib—Face oedema—Cisplatin—esophageal cancer	0.000362	0.00374	CcSEcCtD
Ponatinib—Fluid retention—Capecitabine—esophageal cancer	0.000362	0.00373	CcSEcCtD
Ponatinib—Neuropathy—Capecitabine—esophageal cancer	0.000358	0.00369	CcSEcCtD
Ponatinib—Dry eye—Capecitabine—esophageal cancer	0.000352	0.00363	CcSEcCtD
Ponatinib—Blood creatinine increased—Cisplatin—esophageal cancer	0.000352	0.00363	CcSEcCtD
Ponatinib—Dehydration—Cisplatin—esophageal cancer	0.000349	0.0036	CcSEcCtD
Ponatinib—Petechiae—Methotrexate—esophageal cancer	0.000345	0.00356	CcSEcCtD
Ponatinib—Ecchymosis—Capecitabine—esophageal cancer	0.000345	0.00356	CcSEcCtD
Ponatinib—KIT—lymph node—esophageal cancer	0.000344	0.00521	CbGeAlD
Ponatinib—Hypokalaemia—Cisplatin—esophageal cancer	0.000342	0.00352	CcSEcCtD
Ponatinib—Breast disorder—Cisplatin—esophageal cancer	0.000339	0.0035	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Cisplatin—esophageal cancer	0.000338	0.00349	CcSEcCtD
Ponatinib—Nasopharyngitis—Cisplatin—esophageal cancer	0.000336	0.00346	CcSEcCtD
Ponatinib—Imatinib—PTGS1—esophageal cancer	0.000334	0.0583	CrCbGaD
Ponatinib—Sepsis—Capecitabine—esophageal cancer	0.000331	0.00341	CcSEcCtD
Ponatinib—Blood alkaline phosphatase increased—Capecitabine—esophageal cancer	0.000318	0.00328	CcSEcCtD
Ponatinib—Pancreatitis—Cisplatin—esophageal cancer	0.000318	0.00328	CcSEcCtD
Ponatinib—Abdominal discomfort—Cisplatin—esophageal cancer	0.000311	0.00321	CcSEcCtD
Ponatinib—Pancytopenia—Cisplatin—esophageal cancer	0.000308	0.00318	CcSEcCtD
Ponatinib—CYP3A5—digestive system—esophageal cancer	0.000307	0.00465	CbGeAlD
Ponatinib—Hyperuricaemia—Methotrexate—esophageal cancer	0.000306	0.00316	CcSEcCtD
Ponatinib—ABL1—lymph node—esophageal cancer	0.000299	0.00454	CbGeAlD
Ponatinib—Hot flush—Capecitabine—esophageal cancer	0.000296	0.00305	CcSEcCtD
Ponatinib—Menopausal symptoms—Capecitabine—esophageal cancer	0.000293	0.00303	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Capecitabine—esophageal cancer	0.000293	0.00303	CcSEcCtD
Ponatinib—Atrial fibrillation—Capecitabine—esophageal cancer	0.000292	0.00301	CcSEcCtD
Ponatinib—Blood uric acid increased—Methotrexate—esophageal cancer	0.000289	0.00298	CcSEcCtD
Ponatinib—Acute coronary syndrome—Cisplatin—esophageal cancer	0.000285	0.00294	CcSEcCtD
Ponatinib—Pulmonary embolism—Methotrexate—esophageal cancer	0.000284	0.00293	CcSEcCtD
Ponatinib—Myocardial infarction—Cisplatin—esophageal cancer	0.000284	0.00293	CcSEcCtD
Ponatinib—Neuropathy peripheral—Cisplatin—esophageal cancer	0.000284	0.00293	CcSEcCtD
Ponatinib—Cardiac failure—Capecitabine—esophageal cancer	0.000284	0.00293	CcSEcCtD
Ponatinib—Lethargy—Capecitabine—esophageal cancer	0.000282	0.00291	CcSEcCtD
Ponatinib—Cerebrovascular accident—Capecitabine—esophageal cancer	0.000282	0.00291	CcSEcCtD
Ponatinib—Stomatitis—Cisplatin—esophageal cancer	0.000282	0.00291	CcSEcCtD
Ponatinib—Hyponatraemia—Capecitabine—esophageal cancer	0.000278	0.00287	CcSEcCtD
Ponatinib—Pain in extremity—Capecitabine—esophageal cancer	0.000277	0.00285	CcSEcCtD
Ponatinib—Gastrointestinal haemorrhage—Capecitabine—esophageal cancer	0.000277	0.00285	CcSEcCtD
Ponatinib—ABCG2—lung—esophageal cancer	0.000276	0.00418	CbGeAlD
Ponatinib—Hepatobiliary disease—Cisplatin—esophageal cancer	0.000274	0.00282	CcSEcCtD
Ponatinib—Migraine—Capecitabine—esophageal cancer	0.000272	0.00281	CcSEcCtD
Ponatinib—Skin exfoliation—Methotrexate—esophageal cancer	0.000271	0.00279	CcSEcCtD
Ponatinib—Face oedema—Capecitabine—esophageal cancer	0.000267	0.00276	CcSEcCtD
Ponatinib—Blood creatinine increased—Capecitabine—esophageal cancer	0.000259	0.00267	CcSEcCtD
Ponatinib—Dehydration—Capecitabine—esophageal cancer	0.000257	0.00265	CcSEcCtD
Ponatinib—Ecchymosis—Methotrexate—esophageal cancer	0.000257	0.00265	CcSEcCtD
Ponatinib—CYP3A5—lung—esophageal cancer	0.000256	0.00388	CbGeAlD
Ponatinib—Connective tissue disorder—Cisplatin—esophageal cancer	0.000255	0.00263	CcSEcCtD
Ponatinib—Dry skin—Capecitabine—esophageal cancer	0.000254	0.00262	CcSEcCtD
Ponatinib—Hypokalaemia—Capecitabine—esophageal cancer	0.000252	0.0026	CcSEcCtD
Ponatinib—Visual impairment—Cisplatin—esophageal cancer	0.00025	0.00258	CcSEcCtD
Ponatinib—Breast disorder—Capecitabine—esophageal cancer	0.00025	0.00258	CcSEcCtD
Ponatinib—Aspartate aminotransferase increased—Capecitabine—esophageal cancer	0.000249	0.00257	CcSEcCtD
Ponatinib—Nasopharyngitis—Capecitabine—esophageal cancer	0.000247	0.00255	CcSEcCtD
Ponatinib—Sepsis—Methotrexate—esophageal cancer	0.000246	0.00254	CcSEcCtD
Ponatinib—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000244	0.00252	CcSEcCtD
Ponatinib—Eye disorder—Cisplatin—esophageal cancer	0.000243	0.0025	CcSEcCtD
Ponatinib—Cardiac disorder—Cisplatin—esophageal cancer	0.000241	0.00249	CcSEcCtD
Ponatinib—Flushing—Cisplatin—esophageal cancer	0.000241	0.00249	CcSEcCtD
Ponatinib—Abdominal distension—Capecitabine—esophageal cancer	0.000241	0.00248	CcSEcCtD
Ponatinib—Mediastinal disorder—Cisplatin—esophageal cancer	0.000234	0.00241	CcSEcCtD
Ponatinib—Angina pectoris—Capecitabine—esophageal cancer	0.000233	0.0024	CcSEcCtD
Ponatinib—Arrhythmia—Cisplatin—esophageal cancer	0.000232	0.00239	CcSEcCtD
Ponatinib—CYP3A4—digestive system—esophageal cancer	0.00023	0.00349	CbGeAlD
Ponatinib—Alopecia—Cisplatin—esophageal cancer	0.00023	0.00237	CcSEcCtD
Ponatinib—Abdominal discomfort—Capecitabine—esophageal cancer	0.000229	0.00237	CcSEcCtD
Ponatinib—Pancytopenia—Capecitabine—esophageal cancer	0.000227	0.00234	CcSEcCtD
Ponatinib—CYP2D6—digestive system—esophageal cancer	0.000226	0.00343	CbGeAlD
Ponatinib—Erythema—Cisplatin—esophageal cancer	0.000226	0.00233	CcSEcCtD
Ponatinib—Malnutrition—Cisplatin—esophageal cancer	0.000226	0.00233	CcSEcCtD
Ponatinib—Neutropenia—Capecitabine—esophageal cancer	0.000224	0.00231	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000222	0.00229	CcSEcCtD
Ponatinib—Dermatitis exfoliative—Methotrexate—esophageal cancer	0.000218	0.00225	CcSEcCtD
Ponatinib—Muscle spasms—Cisplatin—esophageal cancer	0.000217	0.00224	CcSEcCtD
Ponatinib—Weight decreased—Capecitabine—esophageal cancer	0.000216	0.00223	CcSEcCtD
Ponatinib—Hyperglycaemia—Capecitabine—esophageal cancer	0.000216	0.00223	CcSEcCtD
Ponatinib—Pneumonia—Capecitabine—esophageal cancer	0.000215	0.00221	CcSEcCtD
Ponatinib—ABCB1—epithelium—esophageal cancer	0.000214	0.00325	CbGeAlD
Ponatinib—Infestation NOS—Capecitabine—esophageal cancer	0.000213	0.0022	CcSEcCtD
Ponatinib—Infestation—Capecitabine—esophageal cancer	0.000213	0.0022	CcSEcCtD
Ponatinib—Vision blurred—Cisplatin—esophageal cancer	0.000213	0.0022	CcSEcCtD
Ponatinib—Acute coronary syndrome—Capecitabine—esophageal cancer	0.00021	0.00217	CcSEcCtD
Ponatinib—Lethargy—Methotrexate—esophageal cancer	0.00021	0.00217	CcSEcCtD
Ponatinib—Cerebrovascular accident—Methotrexate—esophageal cancer	0.00021	0.00217	CcSEcCtD
Ponatinib—Myocardial infarction—Capecitabine—esophageal cancer	0.000209	0.00216	CcSEcCtD
Ponatinib—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000209	0.00216	CcSEcCtD
Ponatinib—Anaemia—Cisplatin—esophageal cancer	0.000209	0.00216	CcSEcCtD
Ponatinib—Jaundice—Capecitabine—esophageal cancer	0.000208	0.00214	CcSEcCtD
Ponatinib—Stomatitis—Capecitabine—esophageal cancer	0.000208	0.00214	CcSEcCtD
Ponatinib—Urinary tract infection—Capecitabine—esophageal cancer	0.000207	0.00214	CcSEcCtD
Ponatinib—Leukopenia—Cisplatin—esophageal cancer	0.000202	0.00209	CcSEcCtD
Ponatinib—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000202	0.00208	CcSEcCtD
Ponatinib—Epistaxis—Capecitabine—esophageal cancer	0.000201	0.00207	CcSEcCtD
Ponatinib—Nilotinib—ABCB1—esophageal cancer	0.000195	0.034	CrCbGaD
Ponatinib—Myalgia—Cisplatin—esophageal cancer	0.000192	0.00199	CcSEcCtD
Ponatinib—Haemoglobin—Capecitabine—esophageal cancer	0.000192	0.00198	CcSEcCtD
Ponatinib—Haemorrhage—Capecitabine—esophageal cancer	0.000191	0.00197	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000191	0.00197	CcSEcCtD
Ponatinib—Hypoaesthesia—Capecitabine—esophageal cancer	0.00019	0.00196	CcSEcCtD
Ponatinib—ABCB1—trachea—esophageal cancer	0.000189	0.00287	CbGeAlD
Ponatinib—ABCG2—lymph node—esophageal cancer	0.000189	0.00286	CbGeAlD
Ponatinib—Oedema peripheral—Capecitabine—esophageal cancer	0.000189	0.00195	CcSEcCtD
Ponatinib—Connective tissue disorder—Capecitabine—esophageal cancer	0.000188	0.00194	CcSEcCtD
Ponatinib—Breast disorder—Methotrexate—esophageal cancer	0.000186	0.00192	CcSEcCtD
Ponatinib—Oedema—Cisplatin—esophageal cancer	0.000185	0.0019	CcSEcCtD
Ponatinib—Visual impairment—Capecitabine—esophageal cancer	0.000184	0.0019	CcSEcCtD
Ponatinib—Infection—Cisplatin—esophageal cancer	0.000183	0.00189	CcSEcCtD
Ponatinib—Nervous system disorder—Cisplatin—esophageal cancer	0.000181	0.00187	CcSEcCtD
Ponatinib—Thrombocytopenia—Cisplatin—esophageal cancer	0.000181	0.00186	CcSEcCtD
Ponatinib—Skin disorder—Cisplatin—esophageal cancer	0.000179	0.00185	CcSEcCtD
Ponatinib—Eye disorder—Capecitabine—esophageal cancer	0.000179	0.00185	CcSEcCtD
Ponatinib—Hyperhidrosis—Cisplatin—esophageal cancer	0.000178	0.00184	CcSEcCtD
Ponatinib—Flushing—Capecitabine—esophageal cancer	0.000178	0.00183	CcSEcCtD
Ponatinib—Cardiac disorder—Capecitabine—esophageal cancer	0.000178	0.00183	CcSEcCtD
Ponatinib—Pancreatitis—Methotrexate—esophageal cancer	0.000175	0.0018	CcSEcCtD
Ponatinib—Angiopathy—Capecitabine—esophageal cancer	0.000174	0.00179	CcSEcCtD
Ponatinib—Mediastinal disorder—Capecitabine—esophageal cancer	0.000173	0.00178	CcSEcCtD
Ponatinib—Chills—Capecitabine—esophageal cancer	0.000172	0.00177	CcSEcCtD
Ponatinib—Arrhythmia—Capecitabine—esophageal cancer	0.000171	0.00176	CcSEcCtD
Ponatinib—Abdominal discomfort—Methotrexate—esophageal cancer	0.000171	0.00176	CcSEcCtD
Ponatinib—Alopecia—Capecitabine—esophageal cancer	0.000169	0.00175	CcSEcCtD
Ponatinib—Pancytopenia—Methotrexate—esophageal cancer	0.000169	0.00174	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000168	0.00173	CcSEcCtD
Ponatinib—Mental disorder—Capecitabine—esophageal cancer	0.000168	0.00173	CcSEcCtD
Ponatinib—Erythema—Capecitabine—esophageal cancer	0.000167	0.00172	CcSEcCtD
Ponatinib—Malnutrition—Capecitabine—esophageal cancer	0.000167	0.00172	CcSEcCtD
Ponatinib—Neutropenia—Methotrexate—esophageal cancer	0.000166	0.00172	CcSEcCtD
Ponatinib—Paraesthesia—Cisplatin—esophageal cancer	0.000166	0.00171	CcSEcCtD
Ponatinib—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000165	0.00171	CcSEcCtD
Ponatinib—Dyspnoea—Cisplatin—esophageal cancer	0.000165	0.0017	CcSEcCtD
Ponatinib—Erectile dysfunction—Methotrexate—esophageal cancer	0.000164	0.00169	CcSEcCtD
Ponatinib—ABCB1—digestive system—esophageal cancer	0.000163	0.00247	CbGeAlD
Ponatinib—Imatinib—ABCB1—esophageal cancer	0.000162	0.0284	CrCbGaD
Ponatinib—Back pain—Capecitabine—esophageal cancer	0.000161	0.00166	CcSEcCtD
Ponatinib—Decreased appetite—Cisplatin—esophageal cancer	0.00016	0.00165	CcSEcCtD
Ponatinib—Muscle spasms—Capecitabine—esophageal cancer	0.00016	0.00165	CcSEcCtD
Ponatinib—Pneumonia—Methotrexate—esophageal cancer	0.00016	0.00165	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000159	0.00164	CcSEcCtD
Ponatinib—Infestation NOS—Methotrexate—esophageal cancer	0.000159	0.00164	CcSEcCtD
Ponatinib—Infestation—Methotrexate—esophageal cancer	0.000159	0.00164	CcSEcCtD
Ponatinib—Pain—Cisplatin—esophageal cancer	0.000158	0.00163	CcSEcCtD
Ponatinib—Vision blurred—Capecitabine—esophageal cancer	0.000157	0.00162	CcSEcCtD
Ponatinib—Stomatitis—Methotrexate—esophageal cancer	0.000155	0.0016	CcSEcCtD
Ponatinib—Anaemia—Capecitabine—esophageal cancer	0.000154	0.00159	CcSEcCtD
Ponatinib—Hepatobiliary disease—Methotrexate—esophageal cancer	0.00015	0.00155	CcSEcCtD
Ponatinib—Epistaxis—Methotrexate—esophageal cancer	0.00015	0.00154	CcSEcCtD
Ponatinib—Leukopenia—Capecitabine—esophageal cancer	0.000149	0.00154	CcSEcCtD
Ponatinib—Body temperature increased—Cisplatin—esophageal cancer	0.000146	0.0015	CcSEcCtD
Ponatinib—Cough—Capecitabine—esophageal cancer	0.000145	0.0015	CcSEcCtD
Ponatinib—Hypertension—Capecitabine—esophageal cancer	0.000144	0.00148	CcSEcCtD
Ponatinib—Haemoglobin—Methotrexate—esophageal cancer	0.000143	0.00148	CcSEcCtD
Ponatinib—Haemorrhage—Methotrexate—esophageal cancer	0.000143	0.00147	CcSEcCtD
Ponatinib—Myalgia—Capecitabine—esophageal cancer	0.000142	0.00146	CcSEcCtD
Ponatinib—Arthralgia—Capecitabine—esophageal cancer	0.000142	0.00146	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000141	0.00145	CcSEcCtD
Ponatinib—Dry mouth—Capecitabine—esophageal cancer	0.000139	0.00143	CcSEcCtD
Ponatinib—Visual impairment—Methotrexate—esophageal cancer	0.000137	0.00142	CcSEcCtD
Ponatinib—Oedema—Capecitabine—esophageal cancer	0.000136	0.0014	CcSEcCtD
Ponatinib—ABCB1—lung—esophageal cancer	0.000136	0.00206	CbGeAlD
Ponatinib—Infection—Capecitabine—esophageal cancer	0.000135	0.00139	CcSEcCtD
Ponatinib—Nervous system disorder—Capecitabine—esophageal cancer	0.000133	0.00138	CcSEcCtD
Ponatinib—Eye disorder—Methotrexate—esophageal cancer	0.000133	0.00137	CcSEcCtD
Ponatinib—Thrombocytopenia—Capecitabine—esophageal cancer	0.000133	0.00137	CcSEcCtD
Ponatinib—Asthenia—Cisplatin—esophageal cancer	0.000132	0.00137	CcSEcCtD
Ponatinib—Cardiac disorder—Methotrexate—esophageal cancer	0.000132	0.00136	CcSEcCtD
Ponatinib—Skin disorder—Capecitabine—esophageal cancer	0.000132	0.00136	CcSEcCtD
Ponatinib—Hyperhidrosis—Capecitabine—esophageal cancer	0.000131	0.00136	CcSEcCtD
Ponatinib—Angiopathy—Methotrexate—esophageal cancer	0.000129	0.00133	CcSEcCtD
Ponatinib—Mediastinal disorder—Methotrexate—esophageal cancer	0.000128	0.00132	CcSEcCtD
Ponatinib—Chills—Methotrexate—esophageal cancer	0.000128	0.00132	CcSEcCtD
Ponatinib—Diarrhoea—Cisplatin—esophageal cancer	0.000126	0.0013	CcSEcCtD
Ponatinib—Alopecia—Methotrexate—esophageal cancer	0.000126	0.0013	CcSEcCtD
Ponatinib—Mental disorder—Methotrexate—esophageal cancer	0.000125	0.00129	CcSEcCtD
Ponatinib—Erythema—Methotrexate—esophageal cancer	0.000124	0.00128	CcSEcCtD
Ponatinib—Malnutrition—Methotrexate—esophageal cancer	0.000124	0.00128	CcSEcCtD
Ponatinib—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000124	0.00128	CcSEcCtD
Ponatinib—Insomnia—Capecitabine—esophageal cancer	0.000123	0.00127	CcSEcCtD
Ponatinib—Paraesthesia—Capecitabine—esophageal cancer	0.000122	0.00126	CcSEcCtD
Ponatinib—Dyspnoea—Capecitabine—esophageal cancer	0.000121	0.00125	CcSEcCtD
Ponatinib—Back pain—Methotrexate—esophageal cancer	0.00012	0.00124	CcSEcCtD
Ponatinib—Dyspepsia—Capecitabine—esophageal cancer	0.00012	0.00124	CcSEcCtD
Ponatinib—Decreased appetite—Capecitabine—esophageal cancer	0.000118	0.00122	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000117	0.00121	CcSEcCtD
Ponatinib—Vomiting—Cisplatin—esophageal cancer	0.000117	0.00121	CcSEcCtD
Ponatinib—Fatigue—Capecitabine—esophageal cancer	0.000117	0.00121	CcSEcCtD
Ponatinib—Vision blurred—Methotrexate—esophageal cancer	0.000117	0.00121	CcSEcCtD
Ponatinib—Rash—Cisplatin—esophageal cancer	0.000116	0.0012	CcSEcCtD
Ponatinib—Pain—Capecitabine—esophageal cancer	0.000116	0.0012	CcSEcCtD
Ponatinib—Constipation—Capecitabine—esophageal cancer	0.000116	0.0012	CcSEcCtD
Ponatinib—Dermatitis—Cisplatin—esophageal cancer	0.000116	0.0012	CcSEcCtD
Ponatinib—Anaemia—Methotrexate—esophageal cancer	0.000115	0.00118	CcSEcCtD
Ponatinib—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000111	0.00115	CcSEcCtD
Ponatinib—Leukopenia—Methotrexate—esophageal cancer	0.000111	0.00115	CcSEcCtD
Ponatinib—Nausea—Cisplatin—esophageal cancer	0.00011	0.00113	CcSEcCtD
Ponatinib—Cough—Methotrexate—esophageal cancer	0.000108	0.00112	CcSEcCtD
Ponatinib—Abdominal pain—Capecitabine—esophageal cancer	0.000108	0.00111	CcSEcCtD
Ponatinib—Body temperature increased—Capecitabine—esophageal cancer	0.000108	0.00111	CcSEcCtD
Ponatinib—Arthralgia—Methotrexate—esophageal cancer	0.000106	0.00109	CcSEcCtD
Ponatinib—Myalgia—Methotrexate—esophageal cancer	0.000106	0.00109	CcSEcCtD
Ponatinib—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000105	0.00108	CcSEcCtD
Ponatinib—Infection—Methotrexate—esophageal cancer	0.000101	0.00104	CcSEcCtD
Ponatinib—Nervous system disorder—Methotrexate—esophageal cancer	9.93e-05	0.00102	CcSEcCtD
Ponatinib—Thrombocytopenia—Methotrexate—esophageal cancer	9.91e-05	0.00102	CcSEcCtD
Ponatinib—Skin disorder—Methotrexate—esophageal cancer	9.84e-05	0.00101	CcSEcCtD
Ponatinib—Hyperhidrosis—Methotrexate—esophageal cancer	9.79e-05	0.00101	CcSEcCtD
Ponatinib—Asthenia—Capecitabine—esophageal cancer	9.76e-05	0.00101	CcSEcCtD
Ponatinib—Pruritus—Capecitabine—esophageal cancer	9.62e-05	0.000993	CcSEcCtD
Ponatinib—Diarrhoea—Capecitabine—esophageal cancer	9.31e-05	0.00096	CcSEcCtD
Ponatinib—ABCB1—lymph node—esophageal cancer	9.3e-05	0.00141	CbGeAlD
Ponatinib—Musculoskeletal discomfort—Methotrexate—esophageal cancer	9.23e-05	0.000952	CcSEcCtD
Ponatinib—Insomnia—Methotrexate—esophageal cancer	9.16e-05	0.000945	CcSEcCtD
Ponatinib—Paraesthesia—Methotrexate—esophageal cancer	9.09e-05	0.000938	CcSEcCtD
Ponatinib—Dyspnoea—Methotrexate—esophageal cancer	9.03e-05	0.000931	CcSEcCtD
Ponatinib—Dizziness—Capecitabine—esophageal cancer	8.99e-05	0.000928	CcSEcCtD
Ponatinib—Dyspepsia—Methotrexate—esophageal cancer	8.91e-05	0.000919	CcSEcCtD
Ponatinib—Decreased appetite—Methotrexate—esophageal cancer	8.8e-05	0.000908	CcSEcCtD
Ponatinib—Gastrointestinal disorder—Methotrexate—esophageal cancer	8.74e-05	0.000902	CcSEcCtD
Ponatinib—Fatigue—Methotrexate—esophageal cancer	8.73e-05	0.0009	CcSEcCtD
Ponatinib—Pain—Methotrexate—esophageal cancer	8.66e-05	0.000893	CcSEcCtD
Ponatinib—Vomiting—Capecitabine—esophageal cancer	8.65e-05	0.000892	CcSEcCtD
Ponatinib—Rash—Capecitabine—esophageal cancer	8.58e-05	0.000885	CcSEcCtD
Ponatinib—Dermatitis—Capecitabine—esophageal cancer	8.57e-05	0.000884	CcSEcCtD
Ponatinib—Headache—Capecitabine—esophageal cancer	8.52e-05	0.000879	CcSEcCtD
Ponatinib—Gastrointestinal pain—Methotrexate—esophageal cancer	8.28e-05	0.000854	CcSEcCtD
Ponatinib—Nausea—Capecitabine—esophageal cancer	8.08e-05	0.000833	CcSEcCtD
Ponatinib—Abdominal pain—Methotrexate—esophageal cancer	8e-05	0.000826	CcSEcCtD
Ponatinib—Body temperature increased—Methotrexate—esophageal cancer	8e-05	0.000826	CcSEcCtD
Ponatinib—Asthenia—Methotrexate—esophageal cancer	7.26e-05	0.000749	CcSEcCtD
Ponatinib—Pruritus—Methotrexate—esophageal cancer	7.16e-05	0.000739	CcSEcCtD
Ponatinib—Diarrhoea—Methotrexate—esophageal cancer	6.93e-05	0.000715	CcSEcCtD
Ponatinib—Dizziness—Methotrexate—esophageal cancer	6.7e-05	0.000691	CcSEcCtD
Ponatinib—Vomiting—Methotrexate—esophageal cancer	6.44e-05	0.000664	CcSEcCtD
Ponatinib—Rash—Methotrexate—esophageal cancer	6.38e-05	0.000659	CcSEcCtD
Ponatinib—Dermatitis—Methotrexate—esophageal cancer	6.38e-05	0.000658	CcSEcCtD
Ponatinib—Headache—Methotrexate—esophageal cancer	6.34e-05	0.000654	CcSEcCtD
Ponatinib—Nausea—Methotrexate—esophageal cancer	6.01e-05	0.00062	CcSEcCtD
Ponatinib—ABCB11—Metabolism—PTGS2—esophageal cancer	4.11e-06	2.69e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—KDR—esophageal cancer	4.09e-06	2.68e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—GSTT1—esophageal cancer	4.09e-06	2.68e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CREBBP—esophageal cancer	4.09e-06	2.68e-05	CbGpPWpGaD
Ponatinib—FGFR4—Signaling Pathways—TP53—esophageal cancer	4.08e-06	2.67e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—EP300—esophageal cancer	4.07e-06	2.66e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CYP19A1—esophageal cancer	4.06e-06	2.66e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—CDKN1A—esophageal cancer	4.06e-06	2.66e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ALDH2—esophageal cancer	4.05e-06	2.65e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—CDKN1A—esophageal cancer	4.05e-06	2.65e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP2A6—esophageal cancer	4.05e-06	2.65e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS2—esophageal cancer	4.03e-06	2.64e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TGFBR2—esophageal cancer	4.01e-06	2.62e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CCND1—esophageal cancer	3.99e-06	2.61e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOTCH1—esophageal cancer	3.99e-06	2.61e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CREBBP—esophageal cancer	3.97e-06	2.6e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CREBBP—esophageal cancer	3.96e-06	2.59e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CASP8—esophageal cancer	3.94e-06	2.58e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CREBBP—esophageal cancer	3.92e-06	2.57e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—EGFR—esophageal cancer	3.91e-06	2.56e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—CDKN1A—esophageal cancer	3.87e-06	2.53e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—CDKN1A—esophageal cancer	3.86e-06	2.53e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EP300—esophageal cancer	3.86e-06	2.53e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—GSTT1—esophageal cancer	3.86e-06	2.52e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NOTCH1—esophageal cancer	3.86e-06	2.52e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EP300—esophageal cancer	3.85e-06	2.52e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—CDKN1A—esophageal cancer	3.85e-06	2.52e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—ENO1—esophageal cancer	3.83e-06	2.51e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS1—esophageal cancer	3.83e-06	2.51e-05	CbGpPWpGaD
Ponatinib—LCK—Innate Immune System—PIK3CA—esophageal cancer	3.83e-06	2.51e-05	CbGpPWpGaD
Ponatinib—ABCB1—Transmembrane transport of small molecules—CREBBP—esophageal cancer	3.83e-06	2.51e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—EGFR—esophageal cancer	3.83e-06	2.5e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—BCL2—esophageal cancer	3.82e-06	2.5e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—NOS3—esophageal cancer	3.82e-06	2.5e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP2A6—esophageal cancer	3.81e-06	2.49e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—SMAD4—esophageal cancer	3.8e-06	2.48e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.79e-06	2.48e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PSME1—esophageal cancer	3.78e-06	2.47e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PSME2—esophageal cancer	3.78e-06	2.47e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—PIK3CA—esophageal cancer	3.77e-06	2.46e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ADH1B—esophageal cancer	3.76e-06	2.46e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—EGFR—esophageal cancer	3.76e-06	2.46e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—EGFR—esophageal cancer	3.75e-06	2.46e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—NOS3—esophageal cancer	3.75e-06	2.45e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP1B1—esophageal cancer	3.74e-06	2.45e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—ERBB2—esophageal cancer	3.71e-06	2.43e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—HMOX1—esophageal cancer	3.71e-06	2.42e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EP300—esophageal cancer	3.68e-06	2.41e-05	CbGpPWpGaD
Ponatinib—LCK—Adaptive Immune System—PIK3CA—esophageal cancer	3.68e-06	2.41e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—MYC—esophageal cancer	3.68e-06	2.41e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EP300—esophageal cancer	3.68e-06	2.4e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EP300—esophageal cancer	3.66e-06	2.4e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—NOS3—esophageal cancer	3.66e-06	2.4e-05	CbGpPWpGaD
Ponatinib—SRC—Hemostasis—TP53—esophageal cancer	3.65e-06	2.38e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CREBBP—esophageal cancer	3.62e-06	2.37e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ENO1—esophageal cancer	3.61e-06	2.36e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS1—esophageal cancer	3.61e-06	2.36e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—MYC—esophageal cancer	3.61e-06	2.36e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—EGFR—esophageal cancer	3.6e-06	2.35e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TYMP—esophageal cancer	3.6e-06	2.35e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—ERBB2—esophageal cancer	3.57e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—EGFR—esophageal cancer	3.57e-06	2.33e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PSME2—esophageal cancer	3.56e-06	2.33e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PSME1—esophageal cancer	3.56e-06	2.33e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—ABCB1—esophageal cancer	3.56e-06	2.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—EGFR—esophageal cancer	3.56e-06	2.33e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—NOS3—esophageal cancer	3.56e-06	2.33e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—NOS3—esophageal cancer	3.55e-06	2.32e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—MYC—esophageal cancer	3.55e-06	2.32e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—EGFR—esophageal cancer	3.53e-06	2.31e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CYP19A1—esophageal cancer	3.52e-06	2.3e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—HIF1A—esophageal cancer	3.51e-06	2.29e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—ERBB2—esophageal cancer	3.51e-06	2.29e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.5e-06	2.29e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CREBBP—esophageal cancer	3.5e-06	2.29e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—EGFR—esophageal cancer	3.47e-06	2.27e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—ERBB2—esophageal cancer	3.43e-06	2.24e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—EP300—esophageal cancer	3.42e-06	2.24e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.41e-06	2.23e-05	CbGpPWpGaD
Ponatinib—SRC—Innate Immune System—PIK3CA—esophageal cancer	3.39e-06	2.22e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—BCL2—esophageal cancer	3.38e-06	2.21e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—MYC—esophageal cancer	3.37e-06	2.2e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—MYC—esophageal cancer	3.36e-06	2.2e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—KDR—esophageal cancer	3.35e-06	2.19e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PTGS2—esophageal cancer	3.35e-06	2.19e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—ERBB2—esophageal cancer	3.33e-06	2.18e-05	CbGpPWpGaD
Ponatinib—FGFR2—Immune System—PIK3CA—esophageal cancer	3.32e-06	2.17e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—CREBBP—esophageal cancer	3.32e-06	2.17e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—ERBB2—esophageal cancer	3.32e-06	2.17e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—EGFR—esophageal cancer	3.29e-06	2.15e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—ERBB2—esophageal cancer	3.29e-06	2.15e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—EGFR—esophageal cancer	3.28e-06	2.15e-05	CbGpPWpGaD
Ponatinib—KIT—Immune System—PIK3CA—esophageal cancer	3.26e-06	2.13e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP1B1—esophageal cancer	3.26e-06	2.13e-05	CbGpPWpGaD
Ponatinib—SRC—Adaptive Immune System—PIK3CA—esophageal cancer	3.26e-06	2.13e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—TPI1—esophageal cancer	3.25e-06	2.13e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.25e-06	2.13e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—NOS3—esophageal cancer	3.24e-06	2.12e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—HMOX1—esophageal cancer	3.21e-06	2.1e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—MYC—esophageal cancer	3.2e-06	2.1e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—CDKN1A—esophageal cancer	3.17e-06	2.07e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOTCH1—esophageal cancer	3.16e-06	2.07e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CCND1—esophageal cancer	3.15e-06	2.06e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.15e-06	2.06e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—EGFR—esophageal cancer	3.14e-06	2.05e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—EGFR—esophageal cancer	3.13e-06	2.05e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—NOS3—esophageal cancer	3.13e-06	2.05e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—EGFR—esophageal cancer	3.12e-06	2.04e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—PIK3CA—esophageal cancer	3.12e-06	2.04e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.12e-06	2.04e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—HIF1A—esophageal cancer	3.11e-06	2.03e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CCND1—esophageal cancer	3.1e-06	2.03e-05	CbGpPWpGaD
Ponatinib—FGFR1—Immune System—PIK3CA—esophageal cancer	3.1e-06	2.02e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Immune System—PIK3CA—esophageal cancer	3.09e-06	2.02e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—ABCB1—esophageal cancer	3.08e-06	2.02e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP1B1—esophageal cancer	3.07e-06	2.01e-05	CbGpPWpGaD
Ponatinib—FGFR2—Disease—PIK3CA—esophageal cancer	3.07e-06	2.01e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CYP19A1—esophageal cancer	3.07e-06	2e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—CDKN1A—esophageal cancer	3.05e-06	2e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—ERBB2—esophageal cancer	3.03e-06	1.98e-05	CbGpPWpGaD
Ponatinib—FGFR3—Signaling Pathways—TP53—esophageal cancer	3.02e-06	1.98e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EP300—esophageal cancer	3.02e-06	1.97e-05	CbGpPWpGaD
Ponatinib—KIT—Disease—PIK3CA—esophageal cancer	3.01e-06	1.97e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GAPDH—esophageal cancer	3e-06	1.96e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—CDKN1A—esophageal cancer	3e-06	1.96e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CRABP1—esophageal cancer	2.97e-06	1.94e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—NOS3—esophageal cancer	2.97e-06	1.94e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—KDR—esophageal cancer	2.97e-06	1.94e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PTGS2—esophageal cancer	2.97e-06	1.94e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CCND1—esophageal cancer	2.94e-06	1.92e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CCND1—esophageal cancer	2.93e-06	1.92e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—CDKN1A—esophageal cancer	2.93e-06	1.92e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—ERBB2—esophageal cancer	2.93e-06	1.91e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EP300—esophageal cancer	2.9e-06	1.9e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CYP19A1—esophageal cancer	2.89e-06	1.89e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CREBBP—esophageal cancer	2.87e-06	1.87e-05	CbGpPWpGaD
Ponatinib—FGFR1—Disease—PIK3CA—esophageal cancer	2.86e-06	1.87e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EP300—esophageal cancer	2.85e-06	1.86e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Disease—PIK3CA—esophageal cancer	2.85e-06	1.86e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—CDKN1A—esophageal cancer	2.84e-06	1.86e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—CDKN1A—esophageal cancer	2.84e-06	1.85e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GNG7—esophageal cancer	2.83e-06	1.85e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—CDKN1A—esophageal cancer	2.81e-06	1.84e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—HMOX1—esophageal cancer	2.8e-06	1.83e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOTCH1—esophageal cancer	2.8e-06	1.83e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EP300—esophageal cancer	2.79e-06	1.82e-05	CbGpPWpGaD
Ponatinib—LYN—Immune System—PIK3CA—esophageal cancer	2.72e-06	1.78e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—PIK3CA—esophageal cancer	2.72e-06	1.78e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PTGS2—esophageal cancer	2.72e-06	1.78e-05	CbGpPWpGaD
Ponatinib—ABL1—Immune System—PIK3CA—esophageal cancer	2.71e-06	1.77e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EP300—esophageal cancer	2.71e-06	1.77e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EP300—esophageal cancer	2.7e-06	1.76e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EP300—esophageal cancer	2.67e-06	1.75e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.65e-06	1.73e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—HMOX1—esophageal cancer	2.64e-06	1.72e-05	CbGpPWpGaD
Ponatinib—KDR—Signaling Pathways—TP53—esophageal cancer	2.63e-06	1.72e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—CDKN1A—esophageal cancer	2.59e-06	1.7e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CCND1—esophageal cancer	2.59e-06	1.69e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—EGFR—esophageal cancer	2.57e-06	1.68e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—NOS3—esophageal cancer	2.57e-06	1.68e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CREBBP—esophageal cancer	2.54e-06	1.66e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—ABCB1—esophageal cancer	2.53e-06	1.65e-05	CbGpPWpGaD
Ponatinib—ABCB11—Metabolism—PIK3CA—esophageal cancer	2.53e-06	1.65e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—MYC—esophageal cancer	2.53e-06	1.65e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.52e-06	1.65e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—CDKN1A—esophageal cancer	2.5e-06	1.64e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.49e-06	1.63e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—MYC—esophageal cancer	2.48e-06	1.62e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—EGFR—esophageal cancer	2.47e-06	1.62e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EP300—esophageal cancer	2.47e-06	1.61e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—EGFR—esophageal cancer	2.43e-06	1.59e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—MYC—esophageal cancer	2.43e-06	1.59e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—ERBB2—esophageal cancer	2.4e-06	1.57e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EP300—esophageal cancer	2.38e-06	1.56e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—CREBBP—esophageal cancer	2.38e-06	1.56e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—EGFR—esophageal cancer	2.37e-06	1.55e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ENO1—esophageal cancer	2.36e-06	1.55e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.36e-06	1.55e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—MYC—esophageal cancer	2.36e-06	1.54e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—MYC—esophageal cancer	2.35e-06	1.54e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.33e-06	1.52e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSME2—esophageal cancer	2.33e-06	1.52e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PSME1—esophageal cancer	2.33e-06	1.52e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—EGFR—esophageal cancer	2.31e-06	1.51e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—EGFR—esophageal cancer	2.3e-06	1.5e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—EGFR—esophageal cancer	2.28e-06	1.49e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—NOS3—esophageal cancer	2.27e-06	1.49e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—EP300—esophageal cancer	2.26e-06	1.48e-05	CbGpPWpGaD
Ponatinib—LCK—Immune System—PIK3CA—esophageal cancer	2.23e-06	1.46e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—MYC—esophageal cancer	2.15e-06	1.41e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—PIK3CA—esophageal cancer	2.15e-06	1.4e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—NOS3—esophageal cancer	2.13e-06	1.39e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—ERBB2—esophageal cancer	2.12e-06	1.39e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CCND1—esophageal cancer	2.12e-06	1.39e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—PIK3CA—esophageal cancer	2.11e-06	1.38e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—EGFR—esophageal cancer	2.1e-06	1.37e-05	CbGpPWpGaD
Ponatinib—FGFR2—Signaling Pathways—TP53—esophageal cancer	2.08e-06	1.36e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—MYC—esophageal cancer	2.07e-06	1.36e-05	CbGpPWpGaD
Ponatinib—LCK—Disease—PIK3CA—esophageal cancer	2.06e-06	1.35e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—CREBBP—esophageal cancer	2.06e-06	1.35e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—CDKN1A—esophageal cancer	2.05e-06	1.34e-05	CbGpPWpGaD
Ponatinib—KIT—Signaling Pathways—TP53—esophageal cancer	2.04e-06	1.33e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—EGFR—esophageal cancer	2.03e-06	1.33e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.01e-06	1.31e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—PIK3CA—esophageal cancer	2e-06	1.31e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—PIK3CA—esophageal cancer	2e-06	1.31e-05	CbGpPWpGaD
Ponatinib—SRC—Immune System—PIK3CA—esophageal cancer	1.98e-06	1.29e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EP300—esophageal cancer	1.95e-06	1.28e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PTGS2—esophageal cancer	1.95e-06	1.27e-05	CbGpPWpGaD
Ponatinib—FGFR1—Signaling Pathways—TP53—esophageal cancer	1.94e-06	1.27e-05	CbGpPWpGaD
Ponatinib—PDGFRA—Signaling Pathways—TP53—esophageal cancer	1.93e-06	1.26e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.89e-06	1.24e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CCND1—esophageal cancer	1.88e-06	1.23e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—NOS3—esophageal cancer	1.84e-06	1.21e-05	CbGpPWpGaD
Ponatinib—SRC—Disease—PIK3CA—esophageal cancer	1.82e-06	1.19e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—CDKN1A—esophageal cancer	1.82e-06	1.19e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—CREBBP—esophageal cancer	1.79e-06	1.17e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—PIK3CA—esophageal cancer	1.76e-06	1.15e-05	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EP300—esophageal cancer	1.73e-06	1.13e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.72e-06	1.13e-05	CbGpPWpGaD
Ponatinib—LYN—Signaling Pathways—TP53—esophageal cancer	1.7e-06	1.11e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—MYC—esophageal cancer	1.7e-06	1.11e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—CREBBP—esophageal cancer	1.69e-06	1.11e-05	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PTGS2—esophageal cancer	1.69e-06	1.1e-05	CbGpPWpGaD
Ponatinib—ABCG2—Metabolism—PIK3CA—esophageal cancer	1.67e-06	1.09e-05	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—EGFR—esophageal cancer	1.66e-06	1.09e-05	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.65e-06	1.08e-05	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—EP300—esophageal cancer	1.62e-06	1.06e-05	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—NOS3—esophageal cancer	1.61e-06	1.05e-05	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—NOS3—esophageal cancer	1.51e-06	9.9e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—MYC—esophageal cancer	1.51e-06	9.84e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—EGFR—esophageal cancer	1.47e-06	9.63e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PTGS2—esophageal cancer	1.47e-06	9.61e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—PIK3CA—esophageal cancer	1.44e-06	9.44e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—EP300—esophageal cancer	1.4e-06	9.17e-06	CbGpPWpGaD
Ponatinib—LCK—Signaling Pathways—TP53—esophageal cancer	1.4e-06	9.13e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PTGS2—esophageal cancer	1.38e-06	9.06e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—PIK3CA—esophageal cancer	1.28e-06	8.36e-06	CbGpPWpGaD
Ponatinib—SRC—Signaling Pathways—TP53—esophageal cancer	1.24e-06	8.08e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—EP300—esophageal cancer	1.22e-06	7.99e-06	CbGpPWpGaD
Ponatinib—CYP3A5—Metabolism—PIK3CA—esophageal cancer	1.2e-06	7.84e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—EP300—esophageal cancer	1.15e-06	7.53e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.11e-06	7.23e-06	CbGpPWpGaD
Ponatinib—CYP2C8—Metabolism—PIK3CA—esophageal cancer	1.04e-06	6.79e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—NOS3—esophageal cancer	9.9e-07	6.47e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PTGS2—esophageal cancer	9.05e-07	5.92e-06	CbGpPWpGaD
Ponatinib—ABCB1—Metabolism—PIK3CA—esophageal cancer	9.04e-07	5.91e-06	CbGpPWpGaD
Ponatinib—CYP2D6—Metabolism—PIK3CA—esophageal cancer	8.52e-07	5.57e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—EP300—esophageal cancer	7.53e-07	4.92e-06	CbGpPWpGaD
Ponatinib—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.57e-07	3.64e-06	CbGpPWpGaD
